A Phase I, double-blind, randomized, vehicle-controlled, dose-finding, safety study of a synthetic nanoparticle-based, T cell priming peptide vaccine against Dengue virus in healthy adults in Switzerland
Switzerland, 2021 - 2022
Reference ID
10.16909-DATASET-43
Producer(s)
GENTON, Blaise, HARTLEY, Mary-Anne
Collections
Department of Ambulatory Care (DDP)